SLS Shareholders Approve 20M Share Increase to Equity Plan at Annual Meeting

SELLAS Life Sciences Group, Inc. announced the voting results from its Annual Meeting of Stockholders held on June 16, 2026. All five proposals were approved by shareholders, including a significant increase in the number of shares available under the company's equity incentive plan and the re-election of two directors.

Key Details

• Equity Plan Expansion: Shareholders approved an amendment to the 2023 Equity Incentive Plan, increasing the number of common stock shares available for issuance by 20,000,000.
• Director Re-election: Robert Van Nostrand and Jane Wasman were re-elected as Class I directors to the Board of Directors, with terms lasting until the 2029 Annual Meeting.
• Auditor Ratified: The appointment of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.